People who have had a stroke are at increased risk of further occlusive vascular events, such as recurrent stroke or myocardial infarction. For people who have had a non‑cardioembolic ischaemic stroke ...

The authors of this study evaluated the relationship between genetic variants, drug metabolism, and clinical effectiveness of prasugrel. First, they sought to identify genetic variants that might ...

Patients with stable cardiovascular disease receiving clopidogrel have similar ischemic risk regardless of which variants of the drug-metabolizing CYP2C19 gene they carry, according to a substudy of ...

Screening patients to assess their clopidogrel resistance status will allow for alternative treatments Screening patients to assess their clopidogrel resistance status will allow for alternative ...

One limitation of the published associations up until that time was that the majority of studies were performed in patients receiving percutaneous coronary interventions (PCI) and often in the setting ...

We described that transgenic mice that overexpress the human CYP2C19 in fetal life, in adult life have smaller hippocampus as well as an altered composition of nerve cells in the hippocampus and ...

Patients’ CYP2C19 genotype plays a significant role in responsiveness to clopidogrel in both the acute and maintenance phases of antiplatelet therapy, accounting for 10% of response variability at 30 ...

First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD640744. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract ...

prior to clopidogrel treatment for stroke patients in the NHS genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that following on from the draft ...